All In Biotech

Drug Trial Radar · NCT05265286

A Study of Repeat Dosing of PEG Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection

A Phase II, Multicentre, Open-label Study to Evaluate the Pharmacokinetic, Safety and Preliminary Efficacy of PEG Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection in Subjects With Severe Hemophilia A

Last checked: Nov 19, 2026Latest source record: May 15, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

15

Actual

Start

Apr 14, 2022

Primary completion

Aug 21, 2022

Study completion Aug 21, 2022

Sponsor

Sponsor type
Industry
First posted
Mar 3, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Male only, from 12 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Primary objective: To assess the pharmacokinetics, Safety and immunogenicity of Repeat Dosing of PEG Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection With Severe Hemophilia A(FRSW117) Secondary objectives: To assess Preliminary efficacy of Repeat Dosing of PEG Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection With Severe Hemophilia A.

Conditions

  • Severe Hemophilia A

Interventions

  • FRSW117Drug

    Subjects of high dose group are being received four doses(50 IU/kg,once a week or every 7 days) of FRSW117. Subjects of low dose group (40 IU/kg,once a week or every 7 days)are being received four doses of FRSW117.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Maximum measured concentration of FVIII:C (Cmax)Time frame: Pre-dose and post dose up to 10 days
  2. Time required for the concentration of the drug to reach half of its original value (T1/2)Time frame: Pre-dose and post dose up to 10 days
  3. Area Under the Curve to Infinity (AUC)Time frame: Pre-dose and post dose up to 10 days
  4. The measure of the efficiency of the body to remove the drug and the unit is the volume of the plasma or blood cleared of drug per unit time (CL)Time frame: Pre-dose and post dose up to 10 days
  5. Evaluation of the level of anti-PEG-rFⅧFc antibody production in participantsTime frame: Pre-dose and post dose up to 36 days
  6. Evaluation of the level of anti-PEG antibody production in participantsTime frame: Pre-dose and post dose up to 36 days

Locations

5 sites in 1 country. Site status is shown where the registry gives one.

  • People'S Hospital of Zhengzhou

    Zhengzhou, Henan, China

  • Affiliated Hospital of Jiangnan University

    Wuxi, Jiangsu, China

  • The Affiliated Hospital of Qingdao University

    Qingdao, Shandong, China

  • People'S Hospital of Rizhao

    Rizhao, Shandong, China

  • Institute of Hematology & Blood Diseases Hospital Chinese Academy of Medical Sciences & Peking Union Medical College.

    Tianjin, Tianjin Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.